Apogee Therapeutics (APGE) Equity Average (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Equity Average data on file, last reported at $1.1 billion in Q1 2026.

• Equity Average for Q1 2026 came in at $1.1 billion, up 55.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 55.35% YoY), and the FY2025 annual result was $810.3 million, up 47.78% from the prior year.
• Equity Average climbed to $1.1 billion in Q1 2026 per APGE's latest filing, from $745.1 million in the prior quarter.
• Over five years, Equity Average peaked at $1.1 billion in Q1 2026 and troughed at -$55.5 million in Q2 2023.
• A 5-year average of $470.2 million and a median of $602.9 million in 2025 frame the typical range for Equity Average.
• The sharpest annual moves came in 2024 and 2025: Equity Average soared 1540.11% in 2024, then slipped 20.05% in 2025.
• A 5-year view of Equity Average shows it stood at -$29.7 million in 2022, then soared by 1426.71% to $394.6 million in 2023, then surged by 83.89% to $725.6 million in 2024, then gained by 2.69% to $745.1 million in 2025, then jumped by 44.92% to $1.1 billion in 2026.
• Business Quant data shows APGE's Equity Average at $1.1 billion in Q1 2026, $745.1 million in Q4 2025, and $602.9 million in Q3 2025.